Lipoprotein-associated phospholipase A2

PLA2G7
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 3D59, 3D5E, 3F96, 3F97, 3F98, 3F9C, 5JAU, 5JAR, 5I9I, 5JAD, 5JAO, 5I8P, 5JAS, 5JAN, 5JAL, 5JAH, 5JAP, 5JAT
Identifiers
Aliases	PLA2G7 , LDL-PLA2, LP-PLA2, PAFAD, PAFAH, Lipoprotein-associated phospholipase A2, phospholipase A2 group VII
External IDs	OMIM: 601690; MGI: 1351327; HomoloGene: 3725; GeneCards: PLA2G7; OMA:PLA2G7 - orthologs
Gene location (Human) Chr. Chromosome 6 (human) [1] Band 6p12.3 Start 46,704,201 bp [1] End 46,735,693 bp [1]
Gene location (Mouse) Chr. Chromosome 17 (mouse) [2] Band 17|17 B3 Start 43,878,989 bp [2] End 43,923,092 bp [2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in amniotic fluid decidua appendix monocyte lymph node spleen mucosa of sigmoid colon rectum endometrium palpebral conjunctiva Top expressed in stroma of bone marrow deep cerebellar nuclei medial vestibular nucleus lobe of cerebellum cerebellar vermis dorsal tegmental nucleus stria vascularis pontine nuclei vestibular sensory epithelium globus pallidus More reference expression data BioGPS More reference expression data
Gene ontology Molecular function calcium-independent phospholipase A2 activity hydrolase activity phospholipid binding hydrolase activity, acting on ester bonds 1-alkyl-2-acetylglycerophosphocholine esterase activity Cellular component cytoplasm extracellular region low-density lipoprotein particle extracellular space Biological process lipid catabolic process lipid oxidation plasma lipoprotein particle oxidation positive regulation of monocyte chemotaxis positive regulation of inflammatory response low-density lipoprotein particle remodeling lipid metabolism platelet activating factor metabolic process Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 7941 27226 Ensembl ENSG00000146070 ENSMUSG00000023913 UniProt Q13093 Q60963 RefSeq (mRNA) NM_001168357 NM_005084 NM_013737 RefSeq (protein) NP_001161829 NP_005075 NP_038765 Location (UCSC) Chr 6: 46.7 – 46.74 Mb Chr 17: 43.88 – 43.92 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) also known as platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A₂ enzyme that in humans is encoded by the PLA2G7 gene. ^{[5] [6]} Lp-PLA₂ is a 45-kDa protein of 441 amino acids. ^[7] It is one of several PAF acetylhydrolases.

Function

In the blood, Lp-PLA₂ travels mainly with low-density lipoprotein (LDL). Less than 20% is associated with high-density lipoprotein (HDL). Several lines of evidence suggest that HDL-associated Lp-PLA₂ may substantially contribute to the HDL antiatherogenic activities. ^[8] It is an enzyme produced by inflammatory cells and hydrolyzes oxidized phospholipids in LDL.

Lp-PLA₂ is platelet-activating factor (PAF) acetylhydrolase (EC 3.1.1.47), a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate. ^[9]

Clinical significance

Lp-PLA₂ is involved in the development of atherosclerosis, ^[7] an observation that has prompted interest as a possible therapeutic target (see, e.g. the investigational drug Darapladib). In human atherosclerotic lesions, two main sources of Lp-PLA₂ can be identified, including that which is brought into the intima bound to LDL (from the circulation), and that which is synthesized de novo by plaque inflammatory cells (macrophages, T cells, mast cells)."

It is used as a marker for cardiac disease. ^[10]

A meta-analysis involving a total of 79,036 participants in 32 prospective studies found that Lp-PLA₂ levels are positively correlated with increased risk of developing coronary heart disease and stroke. ^[11]

See also

• Darapladib

References

1. GRCh38: Ensembl release 89: ENSG00000146070 – Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000023913 – Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, et al. (April 1995). "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase". Nature. 374 (6522): 549–53. Bibcode:1995Natur.374..549T. doi:10.1038/374549a0. PMID   7700381. S2CID   4338858.
6. Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, et al. (April 1996). "Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins". Arteriosclerosis, Thrombosis, and Vascular Biology. 16 (4): 591–9. doi:10.1161/01.ATV.16.4.591. PMID   8624782.
7. Zalewski A, Macphee C (May 2005). "Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target". Arteriosclerosis, Thrombosis, and Vascular Biology. 25 (5): 923–31. doi: 10.1161/01.ATV.0000160551.21962.a7 . PMID   15731492. S2CID   5778538.
8. Tellis CC, Tselepis AD (May 2009). "The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma". Biochimica et Biophysica Acta. 1791 (5): 327–38. doi:10.1016/j.bbalip.2009.02.015. PMID   19272461.
9. "Entrez Gene: PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)".
10. Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A (April 2008). "The effect of darapladib on plasma lipoprotein-associated phospholipase A₂ activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study". Journal of the American College of Cardiology. 51 (17): 1632–41. doi:10.1016/j.jacc.2007.11.079. PMID   18436114.
11. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. (May 2010). "Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies". Lancet. 375 (9725): 1536–44. doi:10.1016/S0140-6736(10)60319-4. PMC   2864403 . PMID   20435228.
    • "Blood protein increases heart disease risk". BBC News. 29 April 2010.

Further reading

• Schröder HC, Perovic S, Kavsan V, Ushijima H, Müller WE (1998). "Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death". Neurotoxicology. 19 (4–5): 683–8. PMID   9745929.
• Feng Y, Walsh CA (June 2001). "Protein-protein interactions, cytoskeletal regulation and neuronal migration". Nature Reviews. Neuroscience. 2 (6): 408–16. doi:10.1038/35077559. PMID   11389474. S2CID   14717115.
• Tjoelker LW, Eberhardt C, Unger J, Trong HL, Zimmerman GA, McIntyre TM, et al. (October 1995). "Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad". The Journal of Biological Chemistry. 270 (43): 25481–7. doi: 10.1074/jbc.270.43.25481 . PMID   7592717.
• Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al. (June 1996). "Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase". The Journal of Clinical Investigation. 97 (12): 2784–91. doi:10.1172/JCI118733. PMC   507371 . PMID   8675689.
• Yamada Y, Yokota M (July 1997). "Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation". Biochemical and Biophysical Research Communications. 236 (3): 772–5. doi:10.1006/bbrc.1997.7047. PMID   9245731.
• Mavoungou E, Georges-Courbot MC, Poaty-Mavoungou V, Nguyen HT, Yaba P, Delicat A, et al. (September 1997). "HIV and SIV envelope glycoproteins induce phospholipase A2 activation in human and macaque lymphocytes". Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 16 (1): 1–9. doi: 10.1097/00042560-199709010-00001 . PMID   9377118.
• Sapir T, Elbaum M, Reiner O (December 1997). "Reduction of microtubule catastrophe events by LIS1, platelet-activating factor acetylhydrolase subunit". The EMBO Journal. 16 (23): 6977–84. doi:10.1093/emboj/16.23.6977. PMC   1170301 . PMID   9384577.
• Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K (December 1997). "A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke". Stroke. 28 (12): 2417–20. doi:10.1161/01.str.28.12.2417. PMID   9412624.
• Yamada Y, Ichihara S, Fujimura T, Yokota M (February 1998). "Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men". Metabolism. 47 (2): 177–81. doi:10.1016/S0026-0495(98)90216-5. PMID   9472966.
• Yoshida H, Imaizumi T, Fujimoto K, Itaya H, Hiramoto M, Yoshimizu N, et al. (September 1998). "A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension". Thrombosis and Haemostasis. 80 (3): 372–5. doi:10.1055/s-0037-1615214. PMID   9759612. S2CID   23924021.
• Lecointe N, Meerabux J, Ebihara M, Hill A, Young BD (May 1999). "Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma". Oncogene. 18 (18): 2852–9. doi: 10.1038/sj.onc.1202645 . PMID   10362256.
• Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, et al. (May 2000). "The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma". American Journal of Human Genetics. 66 (5): 1522–30. doi:10.1086/302901. PMC   1378003 . PMID   10733466.
• Howard KM, Olson MS (June 2000). "The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats". The Journal of Biological Chemistry. 275 (26): 19891–6. doi: 10.1074/jbc.M001462200 . PMID   10748027.
• Min JH, Wilder C, Aoki J, Arai H, Inoue K, Paul L, Gelb MH (April 2001). "Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme". Biochemistry. 40 (15): 4539–49. CiteSeerX   10.1.1.549.9621 . doi:10.1021/bi002600g. PMID   11294621.
• Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, et al. (May 2001). "Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice". Circulation. 103 (20): 2495–500. doi: 10.1161/01.cir.103.20.2495 . PMID   11369691.
• Unno N, Nakamura T, Mitsuoka H, Uchiyama T, Yamamoto N, Saito T, et al. (February 2002). "Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese". Annals of Surgery. 235 (2): 297–302. doi:10.1097/00000658-200202000-00020. PMC   1422429 . PMID   11807372.